Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates [3] - The company recently received FDA approval for Tonmya™, a first-in-class, non-opioid analgesic for the treatment of fibromyalgia, marking the first new prescription medicine approval for this condition in over 15 years [3] - Tonix also markets two treatments for acute migraine in adults and has a development portfolio focused on CNS disorders, immunology, immuno-oncology, and infectious diseases [3] Product Development - Tonmya™ is indicated for the treatment of fibromyalgia in adults [7] - The company is developing TNX-102 SL for acute stress reaction and acute stress disorder, funded by the U.S. Department of Defense [3] - Tonix's immunology portfolio includes TNX-1500, a monoclonal antibody for preventing allograft rejection and treating autoimmune diseases [3] - The infectious disease portfolio features TNX-801, a vaccine for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million over five years with the U.S. DoD [3] Upcoming Events - Seth Lederman, M.D., the CEO of Tonix, will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025 [1] - A webcast of the event will be available on the company's website, with a replay accessible for 90 days post-event [2]
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025